Ipsen rises after cancer treatment drives Q1 beat

Ipsen SA

24/04/2024 09:02

** Shares in Ipsen  IPN.PA  rise 3.2% after the French
biopharma company beat sales expectations in Q1 helped by its
anti-cancer drug Cabometyx
    ** Q1 sales rise 13.3% in constant exchange rates to 822.4
million euros  ($878.82 million), which Jefferies says is 4%
ahead of consensus
    ** " Most key growth drivers are ahead, with the exception 
of Decapeptyl and Bylvay," - Jefferies 
    ** The company also reiterates FY outlook 
    ** The shares are at their highest price since October 2023



($1 = 0.9358 euros)

 (Reporting by Olivier Sorgho)
 ((Olivier.Sorgho@thomsonreuters.com))